Sai Life Sciences Ltd
Sai Life Sciences Ltd (SAILIFE) is scheduled to report results on 5 Nov 2026. Sai Life Sciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹554 crore and net profit of ₹73 crore. The stock last traded at ₹1,528, a market capitalisation of ₹32,447 crore, on a P/E of 88.2. Over the past 52 weeks the stock has ranged between ₹784 and ₹1,697. Figures are as of 6 Oct 2026 and are not real time.
Sai Life Sciences Ltd share price and key metrics
- Current price
- ₹1,528
- Market cap
- ₹32,447 cr
- Stock P/E
- 88.2
- Book value
- ₹117
- ROE
- 15.4%
- ROCE
- 19.6%
- Dividend yield
- 0.00%
- 52w high / low
- 1697/784
Metrics as of 6 Oct 2026. Not real time.
Track Sai Life Sciences Ltd
Cruxal reads every Sai Life Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Sai Life Sciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- 24%
- 3 Years
- 22%
- TTM
- 18%
- 10 Years
- %
- 5 Years
- 42%
- 3 Years
- 227%
- TTM
- 51%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 74%
- 10 Years
- %
- 5 Years
- 9%
- 3 Years
- 13%
- Last Year
- 15%
Sai Life Sciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹554 cr, up 11.7% from ₹496 cr a year earlier. Net profit was ₹73 cr, up 21.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 396 | 440 | 580 | 496 | 537 | 556 | 602 | 554 |
| Expenses | 293 | 320 | 422 | 375 | 392 | 369 | 426 | 406 |
| Operating profit | 102 | 120 | 158 | 121 | 146 | 188 | 177 | 148 |
| OPM % | 26% | 27% | 27% | 24% | 27% | 34% | 29% | 27% |
| Other income | 10 | 9 | 10 | 10 | 15 | 0 | 16 | 4 |
| Interest | 21 | 23 | 11 | 12 | 9 | 10 | 8 | 8 |
| Depreciation | 36 | 34 | 37 | 38 | 40 | 44 | 45 | 46 |
| Profit before tax | 55 | 72 | 119 | 81 | 112 | 134 | 139 | 98 |
| Tax % | 25% | 25% | 26% | 25% | 25% | 25% | 25% | 25% |
| Net profit | 42 | 54 | 88 | 60 | 84 | 100 | 104 | 73 |
| EPS (₹) | — | 2.59 | 4.24 | 2.90 | 4.00 | 4.75 | 4.92 | 3.45 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sai Life Sciences Ltd annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 2,192 | 2,250 |
| Operating profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 634 | 658 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% | 29% | 29% |
| Net profit | 73 | 76 | 61 | 6 | 10 | 83 | 170 | 349 | 362 |
| EPS (₹) | — | — | — | — | — | — | 8.16 | 16.48 | 17.12 |
TTM is the trailing twelve months to the most recent quarter.
Sai Life Sciences Ltd balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 | 21 |
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 | 2,463 |
| Borrowings | 249 | 304 | 637 | 752 | 933 | 928 | 352 | 288 |
| Other liabilities | 247 | 312 | 318 | 527 | 358 | 359 | 665 | 841 |
| Total liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,613 |
| Fixed assets | 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | 1,815 |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 | 270 |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 50 |
| Other assets | 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | 1,477 |
| Total assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,613 |
As reported by the company. Total assets equal total liabilities by construction.
Sai Life Sciences Ltd cash flow
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 129 | 116 | -36 | 105 | 219 | 263 | 314 | 509 |
| Cash from investing | -158 | -262 | -260 | -102 | -99 | -191 | -536 | -395 |
| Cash from financing | 268 | -4 | 296 | 72 | -201 | -95 | 301 | -124 |
| Net cash flow | 239 | -150 | -1 | 75 | -80 | -24 | 79 | -9 |
| Free cash flow | -28 | -157 | -298 | -102 | 148 | 82 | -55 | -83 |
| CFO / operating profit | 90% | 81% | -13% | 90% | 132% | 96% | 82% | 86% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Sai Life Sciences Ltd operating ratios
| Per year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 13% | 9% | 3% | 6% | 11% | 14% | 20% |
| Debtor days | 123 | 136 | 99 | 102 | 85 | 64 | 76 | 62 |
| Inventory days | 86 | 79 | 127 | 179 | 121 | 72 | 93 | 97 |
| Days payable | 207 | 258 | 230 | 279 | 180 | 113 | 253 | 182 |
| Cash conversion cycle | 1 | -43 | -4 | 2 | 25 | 22 | -83 | -24 |
| Working capital days | 55 | 24 | 62 | 42 | 36 | 12 | 66 | 70 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Sai Life Sciences Ltd shareholding pattern
Promoters held 34.53% at Jun 2026, down from 35.15% at Jun 2025. FIIs 19.65% and DIIs 32.71%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Promoters | 35.23% | 35.16% | 35.15% | 34.95% | 34.70% | 34.61% | 34.53% |
| FIIs | 11.72% | 12.36% | 14.57% | 22.50% | 21.41% | 21.17% | 19.65% |
| DIIs | 11.95% | 13.26% | 21.64% | 29.92% | 31.41% | 31.54% | 32.71% |
| Public | 41.08% | 39.21% | 28.64% | 12.65% | 12.49% | 12.69% | 13.11% |
| No. of shareholders | 1,81,122 | 1,40,677 | 1,26,380 | 1,19,705 | 1,14,820 | 1,17,527 | 1,25,096 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Sai Life Sciences Ltd’s next results date?
Sai Life Sciences Ltd’s next results are scheduled for 5 Nov 2026.
- Board meetingConsider and approve quarterly unaudited financial results for Q2 and half-year ended September 30, 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Sai Life Sciences Ltd corporate filings
- Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended 30th September 2026.Company Updatelow impact
- Sai Life Sciences to announce Q2 FY2027 unaudited financial results on 5th November 2026, with a scheduled Board meeting to consider and approve financials and other corporate matters.Board Meetingmedium impact
Cruxal's analysis: Sai Life Sciences Limited has scheduled a Board meeting on 5th November 2026 to approve…
Read the full analysis - Closure of Trading Window relating to Unaudited Financial Result for the Second Quarter and Half Year Ending on 30th September 2026Insider Trading / SASTlow impact
- Sai Life Sciences allots 24,000 equity shares under ESOP planCompany Updatelow impact
Cruxal's analysis: Sai Life Sciences has allotted 24,000 equity shares with a face value of Rs. 1 each…
Read the full analysis - Sai Life Sciences Limited concludes 27th Annual General Meeting with successful passage of all resolutionsAGM/EGMlow impact
Cruxal's analysis: Sai Life Sciences Limited has successfully concluded its 27th Annual General Meeting held…
Read the full analysis - Sai Life Sciences Limited concludes 27th Annual General Meeting; management reaffirms growth strategyAGM/EGMlow impact
Cruxal's analysis: Sai Life Sciences Limited has successfully concluded its 27th Annual General Meeting held…
Read the full analysis - Sai Life Sciences schedules investor conference for 18th September 2026Company Updatelow impact
Cruxal's analysis: Sai Life Sciences has announced an investor conference scheduled for 18th September 2026…
Read the full analysis - Sai Life Sciences schedules investor conference for 14th September 2026Company Updatelow impact
Cruxal's analysis: Sai Life Sciences has announced an investor conference scheduled for 14th September 2026…
Read the full analysis - Sai Life Sciences allots 80,600 equity shares under ESOP plansCompany Updatelow impact
Cruxal's analysis: Sai Life Sciences has allotted 80,600 equity shares with a face value of ₹1 each pursuant…
Read the full analysis - Sai Life Sciences Limited Announces 27th Annual General Meeting Scheduled for September 17, 2026Company Updatelow impact
Cruxal's analysis: Sai Life Sciences Limited has formally notified the stock exchanges regarding the…
Read the full analysis - Sai Life Sciences Ltd: Issuance of Letter to Shareholders regarding Regulation 36(1)(b)Company Updatelow impact
Cruxal's analysis: Sai Life Sciences has issued a communication to shareholders in compliance with…
Read the full analysis - Sai Life Sciences releases Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Sai Life Sciences has filed its Business Responsibility and Sustainability Report (BRSR)…
Read the full analysis - Sai Life Sciences Limited releases Integrated Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Sai Life Sciences has filed its Integrated Annual Report for the financial year 2025-26…
Read the full analysis - Sai Life Sciences Limited Announces 27th Annual General Meeting for September 17, 2026AGM/EGMlow impact
Cruxal's analysis: Sai Life Sciences Limited has issued a notice for its 27th Annual General Meeting (AGM)…
Read the full analysis - Sai Life Sciences Limited Announces 27th Annual General Meeting Scheduled for September 17, 2026Company Updatelow impact
Cruxal's analysis: Sai Life Sciences Limited has formally notified the stock exchanges of its 27th Annual…
Read the full analysis - Sai Life Sciences Limited schedules 27th Annual General Meeting for September 17, 2026AGM/EGMlow impact
Cruxal's analysis: Sai Life Sciences Limited has formally announced its 27th Annual General Meeting (AGM) to…
Read the full analysis - Sai Life Sciences Q1 FY27 Earnings Call Highlights Strategic Pivot to Multi-Modality CRDMO and Capacity ExpansionCompany Updatehigh impact
Cruxal's analysis: Sai Life Sciences reported Q1 FY27 revenue of INR 553 crore, a 12% YoY increase, with CRO…
Read the full analysis - Sai Life Sciences Limited Announces Board Approval of Un-audited Financial Results for Quarter Ended 30 June 2026Company Updatelow impact
Cruxal's analysis: Sai Life Sciences Limited has formally notified the stock exchanges regarding the…
Read the full analysis - Sai Life Sciences releases Monitoring Agency Report for the quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Sai Life Sciences has filed its Monitoring Agency Report for the quarter ended June 30…
Read the full analysis - Sai Life Sciences Limited releases recording of Q1 FY27 earnings callCompany Updatelow impact
Cruxal's analysis: Sai Life Sciences Limited has formally filed the audio recording of its earnings…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.